

BASIC SCIENCE ABSTRACTS



International Parkinson and
Movement Disorder Society

MDS *Virtual* *Congress* 2021

SEPTEMBER 17-22, 2021

www.mdscongress.org

MDS Virtual Congress 2021 Basic Science Abstracts Reference

- 20
Characterization of the Cerebrospinal Fluid Proteome in Patients with Fragile-X Associated Tremor/Ataxia Syndrome
- 86
Neuroinflammation and Anti-Psychotic Drugs Induced Hyperkinesia or Dystonia in Treatment of Organic Brain Psychoses and Schizophrenia
- 137
Comprehensive analysis of non-motor symptoms and their association with quality of life in writer's cramp
- 140
Characterizing the temporal discrimination threshold in musician's dystonia
- 149
Pallidal single unit activity in cervical dystonia patients with unilateral deep brain stimulation
- 150
Multifractal spectrum width of pallidal activity correlates with dystonic severity
- 151
Neural Signals in the Cerebellar Nuclei Gate the Manifestation of Dystonia-Associated Symptoms in Mice
- 153
MDS Basic Scientists Survey demonstrates Potential for Crosspollination between Basic Scientists and MDS
- 204
Intensive rehabilitation program for patients with functional motor disorders: 3-years' experience.
- 214
HSP-SPG5A/CYP7B1: unusual clinical and genetic characteristics in an Indian family
- 215
Differential methylation signatures in Lewy body dementia
- 218
Mutation analysis of BSN gene in patients with multiple system atrophy
- 219
Be aware of pitfalls: Bioinformatic analysis of Cas9-targeted Nanopore sequencing of the RFC1 repeat in CANVAS
- 234
DNA methylation of CDKN2B/CDKN2B-AS1 enhancer in Huntington's disease and lung cancer
- 237
Fine-grained prediction of Huntington's disease stage using a meta-model approach
- 250
Quantifying Tremor in the R6/2 Mouse model of Huntington's Disease
- 273
Neural correlates of executed compared to imagined writing and drawing movements. An fMRI study
- 284
The effects of acute administration of VMAT2 inhibitors on extracellular levels of dopamine, norepinephrine, 5-HT and histamine in the striatum and medial prefrontal cortex

285

Distinct patterns of dyskinetic and dystonic features following D1 or D2 receptor stimulation in a mouse model of parkinsonism

289

TREMOR-LYTIC AND PREFRONTAL-CORTICAL PROPERTIES OF *Nigella sativa* OIL IN PHENOL-INDUCED MICE MODELS OF ESSENTIAL TREMOR

292

Tinospora Cordifolia protects against Rotenone induced degeneration of dopaminergic neurons in mouse model of Parkinson's disease

303

Can event-related oscillations aid in differentiating Parkinson's disease and dementia with Lewy bodies?

324

TNF- α Mediated Neuroinflammation Associated with UPRmt in Kaolin Induced Hydrocephalus Mouse Model

326

Sleep Quality and Nutrition effects in patients with Parkinson's Disease

334

Direct Costs of patients with Parkinson's Disease in a region of the Brazilian Amazon

340

Precision Medicine in Neurodegeneration associated with Pantothenate kinase (PKAN) , its possible?

345

Progressive encephalomyelitis with rigidity and myoclonus in a Mexican patient

351

The alien hand syndrome

365

Efficacy of opicapone according to levodopa's duration of use in Parkinson's disease patients with motor fluctuations

380

Efficacy of opicapone according to different levodopa daily intakes in Parkinson's disease patients with motor fluctuations

417

A new fully implantable Adaptive Deep Brain Stimulation system tested for the first time in patients with Parkinson's Disease

424

Decreased expression of trace amines receptors on lymphocytes in Parkinson's disease

440

RESPONDING TO COVID-19: THE "ALMEIDA-SANG EQUATION" TO PREDICT TOTAL DISEASE SEVERITY IN PARKINSON'S

458

Exploring the Potential Anti-dementia Roles of Selected Herbal Anti-inflammatory Remedies in Parkinson's Disease: Hopes and Challenges

459

Quantitative systems pharmacology modelling of Parkinson's disease to compare anti- α -synuclein therapeutics

463

The mitochondrial targeted drug SBT-272 attenuates dopaminergic neuron loss, α -synuclein burden and neuroinflammation in a mouse model of Parkinson's Disease

473

VMAT2 OVEREXPRESSION REDUCES INTRACELLULAR NEUROMELANIN LEVELS AND ATTENUATES PARKINSON-LIKE PATHOLOGY IN NEUROMELANIN-PRODUCING PARKINSONIAN RATS

477

Gut bacterial tyrosine decarboxylase as a predictive biomarker to identify Parkinson's disease patients with motor fluctuations requiring frequent levodopa administration

484

The GlyT1 inhibitor bitopertin reduces in the 6-OHDA-lesioned rat model of Parkinson's disease

485

Effect of the GlyT1 inhibitor ALX-5407 on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset

486

LY-487,379 alleviates parkinsonism when administered as monotherapy in the MPTP-lesioned marmoset

498

Istradefylline/L-DOPA combination therapy for Parkinson's disease and blood markers of glycolytic energy homeostasis

501

Neuroprotective Epigenetic and DNA-Repair Molecular Mechanisms of Acetyl-L-Carnitine and Astaxanthin Against 6-OHDA Induced Parkinsonism in Aged Rats

502

LY-487,379 enhances the anti-parkinsonian action of a low dose of L-DOPA in the MPTP-lesioned marmoset

504

α -synuclein expression is not mediated by β 2-adrenoreceptor modulation in human dopaminergic cells

508

Efficacy and safety of Levodopa-Carbidopa Intestinal Gel in the treatment of Parkinson's Disease

516

The potential of GBA1 knock-out medaka as a model animal in the search for therapeutic compounds for GBA1-related α -synucleinopathy

518

Effect of simultaneous mGlu2 positive allosteric modulation and orthosteric stimulation combined with 5-HT2A antagonism on psychosis-like behaviours, dyskinesia and parkinsonism in the MPTP-lesioned marmoset

532

Evaluation of a double-target therapeutic in preclinical models of Parkinson's disease

540

Pilot study of Phenotype of Antisense-Oligonucleotide-(ASO)-knockdown of Cerebral-Dopamine-Neurotrophic-Factor (CDNF) as Parkinson Disease model : implications for PD and related Dementia Therapeutics

541

CHAPERONIC PROPENSITIES OF AFRICAN WALNUT AS A THERAPEUTIC TARGET IN MANGANESE-INDUCED PARKINSON-LIKE NEUROPATHOLOGY IN WISTAR RATS

553

Inhibition of GluN2D-containing NMDA receptors alleviates the loss of dopaminergic neurons and behavioral deficits in 6-OHDA-induced model of Parkinson's disease

568

Mapping regional alpha-synuclein seeding capacity in Multiple System Atrophy

586

Automated Midbrain-Pons Ratio using Artificial Intelligence Differentiates PSP from other Atypical Parkinsonian Disorders

593

Plasma microRNA expression profiling in patients with progressive supranuclear palsy. A five-microRNA panel in plasma was identified as a potential biomarker for progressive supranuclear palsy

616

FINANCIAL COST OF PARKINSON'S DISEASE IN BRAZIL IN THE LAST 10 YEARS

640

Challenges in Implementing Relevant Exercise Interventions in Mouse Models of Parkinson's Disease

653

Elucidating multimodal endophenotypes of APOE- ϵ 4 in α -synucleinopathies

656

Perampanel inhibits α -synuclein transmission in Parkinson's disease models

659

Arm swing instructions alter interlimb coordination but not prefrontal cortex activity of Parkinson's disease persons.

672

Cognitive impairment in patients with Alzheimer's disease and Parkinson's disease

674

Association between emotional/cognitive factors and postural control in individuals with Parkinson's disease and freezing of gait

681

RELATION BETWEEN COGNITIVE INHIBITORY CONTROL AND ANTICIPATORY POSTURAL ADJUSTMENT DURING A CONFLICTUAL STEP INITIATION TASK IN PARKINSON'S DISEASE INDIVIDUALS.

682

Effects of levodopa on cognitive functions in Parkinson's disease

685

Cognitive-driven ADL impairment as a predictor for PDD

686

Sociodemographic, cognitive, and clinical factors explaining financial-arithmetic errors in Parkinson's Disease

687

The volume of STN tissue activated by DBS and the strength of its structural connectivity with SMA predicts the effects of STN-DBS on response inhibition

690

Cognitive Diagnostics for Parkinson's Disease: A Novel Digitized Approach Using Non-Motor Symptoms

694

Comparisons Between Parkinson's Disease Patients and At-Risk Individuals: Can Olfactory Deficits and Cognitive Measures Serve as Preclinical Markers?

696

Systematic review of cognitive subtypes derived from data driven approaches in Parkinson's disease

711

The study of genetic factors in motor levodopa-induced complications development in Russian patients with Parkinson's disease

713

The Global Parkinson's Genetics Program (GP2) - a year's progress

725

Rare UQCRC1 variants in Chinese patients with Early Onset Parkinson's Disease

727

SRY as a potential therapeutic target for men with Parkinson's Disease

729

Methylation status of SNCA gene in multiple system atrophy and Parkinson's disease

731

Building a Global Parkinson's Genetics Program (GP2): Clinical Cohorts Integration Working Group

734

Utility of the long-read single-molecule nanopore sequencing for detection of repeat number and epigenetic modifications relevant for X-linked dystonia-parkinsonism

745

Investigating LRRK2 and GBA genetic variability in underrepresented populations

753

Stratified genome-wide association study revealed novel interactions for the top hit Parkinson's disease loci.

756

Gut dysbiosis in Parkinson's disease with motor complications

758

Homozygous PRKN exon 3 deletion in an early-onset Parkinson's disease family from the Kadazan-Dusun ethnic group indigenous to Sabah, Malaysia

765

Analysis of the HLA locus in isolated REM sleep behavior disorder and Lewy body dementia

769

Silencing of hypoxia-inducible factor 1 alpha provokes a neuroprotective response in a SH-SY5Y model of Parkinson's Disease.

770

Antioxidants in foods: A Primary Potential remedy to Neurodegeneration.

771

Integrated Multi-omics of the Gut Microbiome Reveal 2-Hydroxypyridine as a Novel Molecule Relevant to Parkinson's Disease Pathogenesis

773

Targeted plasmaproteome identifies a distinct biomarker panel in early and prodromal Parkinson's disease

774

The role of amylin in Parkinson's disease neurodegenerative process

777

Plasma and fecal short chain fatty acids as predictors for the risk and severity of Parkinson's Disease

778

Rapamycin attenuates nigral and hippocampal alpha-synuclein accumulation in AAV-mediated alpha-synuclein overexpression model of Parkinson's disease

781

CHARACTERIZATION OF LRP10 EXPRESSION IN LEWY BODY DISORDERS AND IPSC-DERIVED BRAIN CELLS

782

Effects of fine particulate matter and cigarette smoking on MPTP-induced dopaminergic neuronal cell death: Implication for Parkinson's disease

783

Impaired glucocerebrosidase transport to lysosomes in cultured macrophages derived from blood monocytic cells of patients with Parkinson's disease associated with mutations in the GBA gene

784

Determination of 5-HT₃ receptor levels with [³H]-GR 65630 binding in hemi-parkinsonian rats with L-DOPA induced dyskinesia

792

CSF MicroRNA Analysis Reveals Angiogenesis And Autophagy Defects In Parkinson's DiseasePatients

794

VPS35 D620N knockin mice recapitulate cardinal features of Parkinson's disease

795

PD phenotype with premotor RBD is associated with a dysbiotic profile of gut microbiota.

800

Biomarker candidates – Peptides identified to be differentially abundant in cerebrospinal fluid of patients with Parkinson's disease

801

Metabolic alterations in a Drosophila model of Parkinson's disease

803

Whole-transcriptome analysis of monocyte-derived macrophages from patients with Parkinson's disease associated with mutations in the GBA gene

813

Interest of optical coherence tomography in Parkinson's disease

818

Distinct memory networks in Parkinson's disease (PD) and Alzheimer's disease (AD): Effects of APOE

823

An Eyes-Open/Closed Manipulation Reveals Disrupted Default Mode Network Connectivity in Parkinson's Disease and REM Sleep Behavior Disorder

825

Compensatory functional mechanisms of response inhibition in Parkinson's Disease with impulse control disorders

826

DAT-IQ improves power to detect longitudinal change in DaT deficit in SURE-PD3

832

Movement-related dynamics of β - γ phase-amplitude coupling in repetitive movement tasks of Parkinson disease

850

Characteristics of the amyloid beta networks in Parkinson's disease patients: a PPMI study

858

Altered functional connectivity of the hippocampus in posterior-cortical subtype of cognitive impairment in Parkinson's disease

873

Regional brain iron and gene expression variation in Parkinson's disease

874

Progression of brain atrophy in Parkinson's disease is shaped by connectome and local vulnerability

876

VMAT2 availability in Parkinson's Disease with Rapid Eye Movement Sleep Behaviour Disorder

879

The role of network connectivity in shaping the progression of cortical atrophy in Parkinson's disease

882

Neuroanatomical signatures of genetic risk for Parkinson's Disease in healthy adults

887

Changes in the cerebellar activity during task based and resting state fMRI in Parkinson's disease patients with mild cognitive impairment

895

Pallidal deep brain stimulation entrains finely tuned gamma oscillations in motor cortex

- 900
Deficient interhemispheric connectivity underlies movement irregularities in Parkinson's disease
- 901
LFP spectral features associated with therapy complications in typical and early onset Parkinson's disease
- 904
The aperiodic component of cortical Local Field Potentials is affected in Parkinson's Disease and Essential Tremor.
- 906
Decrease in STN high frequency activity after microelectrode insertion during DBS surgery for Parkinson's disease
- 907
Movement vigor is differentially encoded in motor cortex and globus pallidus in Parkinson disease
- 908
Long-term effect of safinamide on primary motor cortex excitability and plasticity in Parkinson's disease: a TMS study
- 909
Beta synchronization of the subthalamic nucleus during self-initiated and externally generated movement in parkinsonian patients in OFF and ON states
- 917
Evoked potentials as biomarker for deep brain stimulation programming in Parkinson's disease
- 920
Distinct oscillatory fingerprints in dyskinesias mediated by D1 versus D2 receptors
- 922
Directional deep brain stimulation causes distinct intraoperative LFPs in Parkinson's patients
- 928
Progression of neuroinflammation in patients with isolated REM sleep behavior disorder. A 11C-PK11195 PET study
- 945
Is dopamine replacement therapy an addictive drug?
- 952
Fecal Calprotectin in Parkinson's Disease and Multiple System Atrophy
- 964
Hyperhidrosis in Parkinson's disease: a 3-year prospective cohort study
- 977
Dopamine dysregulation syndrome in Parkinson's disease after COVID-19. Case report.
- 999
A53T-SNCA-BAC transgenic mouse exhibits multiple prodromal symptoms of Parkinson's disease: Gastrointestinal dysfunction, hyposmia and RBD-like behavior.
- 1018
Role of S100B in the Pathogenesis of Parkinson's Disease
- 1023
Sphingosine-1-phosphate, motor severity and progression in Parkinson's disease (MARK-PD)
- 1032
Evaluation of Acoustic Features of Speech for Monitoring Parkinson's Disease Progression
- 1034
Peripheral immune profile and neutrophil-to-lymphocyte ratio in Parkinson's disease
- 1037
Motor Function Test Protocol for Parkinsonian Triad in Rodent Model of Parkinson's Disease

1040

Piecing Together the Gut Microbiome in Parkinson's Disease: A Meta-Analysis

1049

CAN DANCE AS A COMPLEMENTARY THERAPY REDUCE THE OCCURRENCE OF DEPRESSION AND APATHY IN PEOPLE WITH PARKINSON'S DISEASE?

1058

extrapyramidal involvement in Horizontal gaze palsy with progressive scoliosis (HGPPS).

1060

Characterization of a mouse model of PDE10A-related autosomal-dominant movement disorder.

1071

Cellular Modeling of Tyrosine Hydroxylase Deficiency Recapitulates Patient Phenotypes and Response to Treatment.

1092

Transcranial direct current stimulation-related changes in postural responses to perturbations are not influenced by baseline clinical characteristics in Parkinson's disease.

1101

Effects of freezing gait and medication on postural control during prolonged standing in individuals with Parkinson's disease

1109

RISK FACTORS FOR FALLS AMONG PEOPLE WITH PARKINSON 'S DISEASE

1111

Correction of gait pattern in Parkinson's disease

1131

Comparative Measurement of Balance between Parkinson Disease and Spinocerebellar Ataxia - A Dynamic Posturography Study

1165

The impact of lockdown due to the COVID-19 pandemic on Asian cervical dystonia patients treated with Botulinum toxin injections

1181

MOLECULAR-GENETIC ASPECTS OF WILSON'S DISEASE IN UKRAINE

1195

The satisfaction with life and treatment scale (SLTS-7) in patients with Parkinson's disease

1201

Prevalence of Restless Legs Syndrome in the South African population

1204

New insight into REM-sleep atonia circuits underlying REM sleep behavior disorder in living humans

1214

Studying of the correlation between the severity of ischemic stroke and the severity of post-stroke spasticity in the early recovery period

1246

Comparability of frame systems for the implantation of DBS electrodes in Parkinson's disease

1248

Comparison of Activa PC to Percepttm impedance assessment across device exchanges

1252

Effect of deep brain stimulation on quality of life of patients with Parkinson's Disease

1273

Automatic Estimation of MDS-UPDRS Gait Scores from Videos with Multi-Rater Disagreements

1287

Measures of Physical Activity in Parkinson's Disease (MAPD)

1292

Validity of quantitative parameters for analyzing gait motion in PD patients after STN-DBS

1316

Open-Source Tremor Tracking for MR-guided Focused Ultrasound (MRgFUS): An Objective Approach for Monitoring Treatments

1318

Effect of dopaminergic treatment on digital sensor features in Phase II PASADENA Part 1 in early Parkinson's disease

1329

Clinical correlates of sleep disturbances in children with Tourette syndrome